A recent study published in Phlebology: The Journal of Venous Disease has unveiled vital information about treating telangiectasia, those pesky surface-level blood vessels. Led by researchers Oksana V Bukina, Aleksandr A Sinitsyn, Oksana I Efremova, and Andrey V Pelevin, this study aimed to determine which treatment method is most effective: hypertonic glucose (HG) or various concentrations of sodium tetradecyl sulfate (STS).
Telangiectasia, often a concern for cosmetic and therapeutic reasons, can be effectively treated with sclerotherapy. The primary goal of this study was to assess the disappearance of these bothersome blood vessels, graded on a scale from 0 to 5.
A total of 116 women participated in an 8-week follow-up, divided into four groups: HG 75%, STS 0.05%, STS 0.1%, and STS 0.15%. The results were clear – the groups treated with STS, especially STS 0.05%, STS 0.1%, and STS 0.15%, showed significantly less effective results compared to the HG group after 56 days.
In simple terms, when it comes to eliminating telangiectasias, low concentrations of sodium tetradecyl sulfate (STS) are less effective than hypertonic glucose (HG) at the 75% concentration.
This research, registered under ClinicalTrials.gov as NCT04132323, offers a valuable guide for both medical practitioners and patients seeking optimal outcomes in addressing telangiectasia. The study by Oksana V Bukina, Aleksandr A Sinitsyn, Oksana I Efremova, and Andrey V Pelevin highlights the significance of evidence-based decision-making in the field of venous disorders.
For a comprehensive understanding of this study, read the full article in Phlebology: The Journal of Venous Disease available here.
For more phlebology articles and insights, visit the official website of Phlebology: The Journal of Venous Disease here.
